Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes
Information source: Walter Reed Army Medical Center
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P) (Drug)
Phase: N/A
Status: Completed
Sponsored by: Walter Reed Army Medical Center Official(s) and/or principal investigator(s):
KRAIG S. BOWER, MD, Principal Investigator, Affiliation: Walter Reed Army Medical Center
Summary
The objective of this study is to evaluate the effect of brimonidine tartrate ophthalmic
solution 0. 15% (Alphagan P) on pupil diameter under different luminance conditions.
Clinical Details
Study design: Time Perspective: Longitudinal
Eligibility
Minimum age: 18 Years.
Maximum age: 50 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Adult active duty personnel between 18 and 50 years of age with best corrected visual
acuity of 20/20 or better.
Exclusion Criteria:
- Patients not meeting above stated age criteria
- Females that are pregnant or lactating (non pregnant females of childbearing
potential will have pregnancy test prior to participating in study)
- History of serious ocular, neurological, cardiovascular disease
- History of severe systemic disease
- History of arrhythmias or high blood pressure
- Patients currently taking any type of ocular or systemic medications except
multivitamins.
- Patients with abnormal pupil shape, Addie's pupil, anisocoria, or abnormal pupil
defect.
Locations and Contacts
Walter Reed Army Medical Center, Washington, District of Columbia 20307, United States
Additional Information
Last updated: December 19, 2006
|
